Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06005818 | Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)(MRD GATE RCC) | recruiting | Phase 2 | 100 | University of Alabama at BirminghamOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT07218692 | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2025 |
| clinicaltrials |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Oct 16, 2025 | clinicaltrials |
| NCT05931393 | Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | recruiting | Phase 2 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06310759 | Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer(UROSCOUT-1) | recruiting | — | 3,000 | Tampere University HospitalOTHER | 4 | Oct 10, 2025 | clinicaltrials |
| NCT03438708 | Prior Axitinib as a Determinant of Outcome of Renal Surgery(PADRES) | active not recruiting | Phase 2 | 22 | University of California, San DiegoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05148546 | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer(NESCIO) | active not recruiting | Phase 2 | 69 | The Netherlands Cancer InstituteOTHER | 2 | Sep 30, 2025 | clinicaltrials |
| NCT06727214 | Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer(AssiutU) | not yet recruiting | — | 87 | Sara Mahmoud Ahmed MahmoudOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT05965856 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06934057 | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma(CABOLD) | recruiting | Phase 4 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT07190638 | Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial(CORTEX) | recruiting | N/A | 80 | Brazilian Institute of Robotic SurgeryOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04678362 | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma(TALASUR) | recruiting | Phase 2 | 50 | Centre Francois BaclesseOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07187063 | Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer | recruiting | N/A | 56 | Lahey ClinicOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06917560 | Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study | active not recruiting | — | 400 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07172386 | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC | recruiting | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07175480 | PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk(Perfumer) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04163289 | Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation(PERFORM) | active not recruiting | Phase 1 | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06848868 | Ambulatory Flexible URS for UTUC Surveillance | recruiting | Phase 1 | 10 | Chinese University of Hong KongOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07164950 | Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients | recruiting | N/A | 58 | Sheng ZhangOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06351904 | A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy | recruiting | Phase 1 | 72 | Ractigen Therapeutics.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(COSMIC-313) | active not recruiting | Phase 3 | 855 | ExelixisINDUSTRY | 25 | Sep 10, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 390 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2025 | clinicaltrials |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | not yet recruiting | Phase 3 | 116 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07166445 | Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT | recruiting | — | 1,000 | Peking University First HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial(PROBE) | recruiting | Phase 3 | 364 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06302569 | Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma(REPRINT) | recruiting | Phase 2 | 23 | Giuseppe ProcopioOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07159191 | Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT06262516 | Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma | recruiting | N/A | 94 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05318573 | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 120 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05782400 | Multiomics Approach in Metastatic Clear Renal Cell Carcnoma | active not recruiting | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06255223 | A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | recruiting | Phase 2 | 35 | Jinling Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06571708 | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)(NeoSTOP-IT) | recruiting | Phase 2 | 36 | Columbia UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 90 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06181266 | A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer(PARADIGM-1) | active not recruiting | Phase 1 | 22 | Prokarium LtdINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT07126119 | Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC | recruiting | Phase 2 | 35 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06983210 | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma(GRAPE) | recruiting | Phase 2 | 43 | Nagoya UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07122414 | A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 80 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07118813 | Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment | recruiting | — | 400 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06632951 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)(LIVIGNO-3) | active not recruiting | Phase 2 | 150 | AbbVieINDUSTRY | 8 | Aug 11, 2025 | clinicaltrials |
| NCT07113977 | Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy | not yet recruiting | Early Phase 1 | 30 | Wei GuanOTHER | 0 | Aug 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 21, 2025source: clinicaltrials